Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Efferocytosis is the process by which apoptotic cells are cleared from tissue by phagocytic cells. The removal of apoptotic cells prevents them from undergoing secondary necrosis and releasing their inflammation-inducing intracellular contents. Efferocytosis also limits tissue damage by increasing immunosuppressive cytokines and leukocytes and maintains tissue homeostasis by promoting tolerance to antigens derived from apoptotic cells. Thus, tumor cell efferocytosis following cytotoxic cancer treatment could impart tolerance to tumor cells evading treatment-induced apoptosis with deleterious consequences in tumor residual disease. We report here that efferocytosis cleared apoptotic tumor cells in residual disease of lapatinib-treated HER2+ mammary tumors in MMTV-Neu mice, increased immunosuppressive cytokines, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg). Blockade of efferocytosis induced secondary necrosis of apoptotic cells, but failed to prevent increased tumor MDSCs, Treg, and immunosuppressive cytokines. We found that efferocytosis stimulated expression of IFN-γ, which stimulated the expression of indoleamine-2,3-dioxegenase (IDO) 1, an immune regulator known for driving maternal-fetal antigen tolerance. Combined inhibition of efferocytosis and IDO1 in tumor residual disease decreased apoptotic cell- and necrotic cell-induced immunosuppressive phenotypes, blocked tumor metastasis, and caused tumor regression in 60% of MMTV-Neu mice. This suggests that apoptotic and necrotic tumor cells, via efferocytosis and IDO1, respectively, promote tumor ‘homeostasis’ and progression. Significance: These findings show in a model of HER2+ breast cancer that necrosis secondary to impaired efferocytosis activates IDO1 to drive immunosuppression and tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Molecular signatures of tolerogenic wound healing often are observed in cancers, correlating with poor outcome and disease progression (20,21), although their origins are unclear.”
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 10×
“Flow cytometry confirmed that TRegs (CD45 + CD3 + CD4 + CD8 neg FoxP3 + ) were increased in L/B-treated tumors (Figure 3E).”
BackgroundInfluentialABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Inflammation and metabolism in tissue repair and regeneration
Eming, S. A., Wynn, T. A., & Martin, P. (2017) · Science · doi:10.1126/science.aam7928 · Cited by 1,369
Phagocytosis and clearance of apoptotic cells is mediated by MER
Scott, R. S., McMahon, E. J., Pop, S. M., Reap, E. A., Caricchio, R., Cohen, P. L., Earp, H. S., & Matsushima, G. K. (2001) · Nature · doi:10.1038/35075603 · Cited by 1,215 · cited 1×
“Second, ACs that are not dispatched ultimately lose membrane integrity and undergo secondary necrosis, releasing intracellular contents that trigger inflammation (11-14), tissue damage and in some cases, autoimmunity (5,11,15,16).”
BackgroundTAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response
Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. A., & Lemke, G. (2007) · Cell · doi:10.1016/j.cell.2007.10.034 · Cited by 1,055 · cited 1×
“Second, ACs that are not dispatched ultimately lose membrane integrity and undergo secondary necrosis, releasing intracellular contents that trigger inflammation (11-14), tissue damage and in some cases, autoimmunity (5,11,15,16).”
BackgroundLemke, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009076 · Cited by 598 · cited 2×
“The receptor tyrosine kinase MerTK is required for efferocytosis by macrophages and other phagocytes (5-7).”
BackgroundEfferocytosis Signaling in the Regulation of Macrophage Inflammatory Responses
Elliott, M. R., Koster, K. M., & Murphy, P. S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601520 · Cited by 440
Mühlbauer, M., Fleck, M., Schütz, C., Weiss, T., Froh, M., Blank, C., Schölmerich, J., & Hellerbrand, C. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.007 · Cited by 378
Cited by
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Tang, K., Wu, Y.-H., Song, Y., & Yu, B. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01080-8 · Cited by 365
Regulation of efferocytosis as a novel cancer therapy
Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100
Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis
Wei, Y.-T., Wang, X.-R., Yan, C., Huang, F., Zhang, Y., Liu, X., Wen, Z.-F., Sun, X.-T., Zhang, Y., Chen, Y.-Q., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4260 · Cited by 80
Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution
Sukka, S. R., Ampomah, P. B., Darville, L. N. F., Ngai, D., Wang, X., Kuriakose, G., Xiao, Y., Shi, J., Koomen, J. M., McCusker, R. H., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01115-7 · Cited by 82
“In this context, an important challenge in pro-efferocytosis and resolution therapy in general 71 , and for therapies that boost macrophage Trp metabolism in particular 72 , is to avoid activating an immunosuppressive response that could lower defence against tumour cells.”
Liang, X., Luo, M., Shao, B., Yang, J., Tong, A., Wang, R., Liu, Y., Jun, R., Liu, T., Yi, T., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12272 · Cited by 68
Metadata
- Authors
- Werfel, T. A., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V., Gonzales-Ericsson, P. I., Nixon, M. J., James, J. L., Balko, J. M., Scherle, P. A., Koblish, H. K., & Cook, R. S.
- Venue
- Cancer Research
- Published
- 2019-01-01
- Volume
- 79
- Issue
- 1
- Pages
- 171-182
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2900429601
- Cited by
- 92
- References
- 12
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-1106
- The paper
- Werfel, T. A., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V., Gonzales-Ericsson, P. I., Nixon, M. J., James, J. L., Balko, J. M., Scherle, P. A., Koblish, H. K., & Cook, R. S. (2019). Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-1106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.